hero-line-left hero-line-top
For Life Sciences

Bringing together healthcare innovators

Syapse partners with life sciences companies to deliver real-world evidence to support decision-making and foster collaboration among all the stakeholders working to maximize benefit for patients.


Work with us

Syapse is the preferred partner for life sciences companies looking to tap into the power of real-world data for oncology product portfolio planning, research and development, FDA submissions, and post-market analyses.

  • Research: access a web-based tool for exploring shared, de-identified data. Users can interact with real-world treatment trends, clinical characteristics, and outcomes for selected cohorts
  • Trials: identify the best sites and potential candidates for your molecularly targeted interventional trials; real-world patient distribution insights boost trial enrollment
  • Regulatory: create high quality, fully integrated clinical genomic datasets that can be used to accelerate FDA approvals
  • Commercial: access analytics dashboards and custom-designed collaborations that can guide your physician education and outreach efforts and shape post-market activities
As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients. Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care.”
Mike Nohaile
Mike Nohaile
SVP of Strategy, Commercialization, and Innovation at Amgen


Let’s talk

If you’d like to learn more about Syapse, tell us a little about yourself and we will reach out as soon as possible. 

What's new

Syapse Looks to Dive Deeper Into Large Health Systems for Data-Driven Cancer Insights

Fresh off a $68 million funding round, Syapse is moving quickly to expand its network of partnerships with life sciences companies, health systems, molecular laboratories, and regulators. “We’re right in the middle of growth mode right now,” CEO Ken Tarkoff said of the 13-year-old company. The San Francisco-based maker of software to support precision oncology care and drug discovery also raised $30 million in a round that closed in May 2020.



The Innovation Engine That Could: Why It is Important to Carve Out Time to Innovate

Syapse made its presence known in the precision medicine and real-world evidence space over a decade ago. In this time, the use and understa…